kabutan

BrightPath Biotherapeutics, Net Income Forecast for the Fiscal Year Loss Widened in Downward Revision

Fri Mar 13, 2026 3:30 pm JST Revision

4594 BrightPath Biotherapeutics Co., Ltd. 【J-GAAP】

Guidance Update Report

BrightPath Biotherapeutics Co., Ltd. <4594> [TSE Growth] announced a performance revision after the market closed on March 13th (15:30). The net income/loss (non-consolidated) forecast for the fiscal year ending March 2026 has been revised downward from an expected loss of 1.16 billion yen to a loss of 1.31 billion yen (compared to a loss of 1.15 billion yen in the previous period), indicating an expansion in the loss margin.

Based on the downwardly revised full-year plan announced by the company, our calculation indicates that the October to March period (second half) net income/loss has been revised downward from an expected loss of 0.70 billion yen to a loss of 0.84 billion yen (compared to a loss of 0.61 billion yen in the same period of the previous year), indicating an expansion in the loss margin.

Kabutan News

Guidance Update

Second Half Update

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2025 Prev 0 -718 -704 -704 -5.3 0 Nov 14, 2025 J-GAAP
Oct - Mar, 2025 New 0 -851 -848 -849 -6.4 0 Mar 13, 2026 J-GAAP
Revision Rate － -18.5% -20.5% -20.6% -20.6%

Full Year Update

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2026 Prev 0 -1,182 -1,164 -1,166 -8.9 0 May 9, 2025 J-GAAP
Mar, 2026 New 0 -1,315 -1,308 -1,311 -10.0 0 Mar 13, 2026 J-GAAP
Revision Rate － -11.3% -12.4% -12.4% -12.4%

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2024 1 -618 -610 -613 -7.5 0 May 9, 2025 J-GAAP
Oct - Mar, 2025 Guidance 0 -851 -848 -849 -6.4 0 Mar 13, 2026 J-GAAP
YoY － -37.7% -39.0% -38.5% +14.4%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2024 0 -1,155 -1,158 -1,168 -18.2 0 May 10, 2024 J-GAAP
Mar, 2025 1 -1,160 -1,147 -1,151 -14.1 0 May 9, 2025 J-GAAP
Mar, 2026 Guidance 0 -1,315 -1,308 -1,311 -10.0 0 Mar 13, 2026 J-GAAP
YoY － -13.4% -14.0% -13.9% +29.5%

Related Articles